Antibiotic regimens for an adult odontogenic infection: the drug, the dose and the days once a drug is genuinely indicated

What it says#

This entry reports regimens, not indications. The question of whether to prescribe at all is answered by the ADA's 2019 guideline itself and is covered by the sibling entry in this directory: with likely negligible benefits and potentially large harms, that panel recommended against using antibiotics in most clinical scenarios, whether or not definitive conservative dental treatment was immediately available, and recommended them only for patients with systemic involvement, for example malaise or fever, or when the risk of progression to systemic involvement is high. Nothing below changes that. The point of this page is what to write once you have decided a drug is genuinely indicated.

The ADA panel's first-line regimens for an immunocompetent adult are oral amoxicillin 500 mg three times a day for 3 to 7 days, or oral penicillin VK 500 mg four times a day for 3 to 7 days. The panel notes that amoxicillin is preferred over penicillin because it is more effective against various gram-negative anaerobes and has a lower incidence of gastrointestinal side effects.

For a patient with a reported penicillin allergy, with or without a history of anaphylaxis, angioedema or hives with penicillin, ampicillin or amoxicillin, the panel suggests oral cephalexin 500 mg four times a day for 3 to 7 days, or oral azithromycin with a loading dose of 500 mg on day 1 followed by 250 mg for an additional four days, or oral clindamycin 300 mg four times a day for 3 to 7 days. The panel puts that list in order, balancing the desirable and undesirable consequences of each drug, and notes that some carry a greater risk of harm, allergic reactions with penicillin and Clostridioides difficile infection with clindamycin. It also records that although approximately 10% of the population self-reports a penicillin allergy, less than 1% of the entire population is truly allergic, and that clinicians should proceed with non-penicillin drug class antibiotics until a true allergy is confirmed.

If a patient without a penicillin allergy fails to respond to first-line treatment, meaning no improvement in symptoms or progression to a more severe state, the panel suggests either complementing the first-line drug with oral metronidazole 500 mg three times a day for 7 days, or discontinuing the first-line drug and prescribing oral amoxicillin with clavulanate 500/125 mg three times a day for 7 days, to improve activity against gram-negative anaerobes. If a patient in the penicillin-allergy branch fails to respond to cephalexin, azithromycin or clindamycin, the panel suggests complementing the first-line drug with the same metronidazole regimen. The panel also notes that moxifloxacin has a reasonable spectrum for oral infections but carries FDA boxed warnings, and that an antibiotic with a similar spectrum started before the patient presented can be continued.

The FDA labels are the other half of the picture, and they are worth reading because they say what the manufacturer's evidence actually supports. The amoxicillin label gives adults and patients over 40 kg 500 mg every 12 hours or 250 mg every 8 hours for mild to moderate ear, nose and throat, skin and skin structure, or genitourinary infections, and 875 mg every 12 hours or 500 mg every 8 hours for severe ones, with treatment continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic. The penicillin V potassium label carries an oral indication that is unmistakably dental, fusospirochetosis, Vincent's infection of the oropharynx, dosed at 250 to 500 mg every 6 to 8 hours for mild to moderately severe infections, and it adds the note quoted above about necessary dental care. The cephalexin label gives adults and patients at least 15 years old 250 mg every 6 hours, or 500 mg every 12 hours, for 7 to 14 days, with up to 4 grams daily in two to four divided doses for more severe infections. The azithromycin label's adult regimen for mild community-acquired pneumonia, second-line pharyngitis or tonsillitis and uncomplicated skin infections is 500 mg as a single dose on Day 1 followed by 250 mg once daily on Days 2 through 5, which is the regimen the ADA panel borrowed. The clindamycin label gives adults 150 to 300 mg every 6 hours for serious infections and 300 to 450 mg every 6 hours for more severe infections, is indicated for serious infections caused by susceptible anaerobic bacteria, says its use should be reserved for penicillin-allergic patients or patients for whom penicillin is inappropriate, and carries a boxed warning for C. difficile-associated diarrhea and colitis. The metronidazole label gives a usual adult oral dose of 7.5 mg/kg every six hours, approximately 500 mg for a 70 kg adult, with a maximum of 4 grams in 24 hours and a usual duration of 7 to 10 days, and states that indicated surgical procedures should be performed in conjunction with metronidazole therapy. The amoxicillin and clavulanate label gives adults and patients over 40 kg 500 mg or 875 mg every 12 hours, or 250 mg or 500 mg every 8 hours, based on the amoxicillin component, with the 875 mg every 12 hours or 500 mg every 8 hours regimen for severe infections and respiratory tract infections.

None of these labels carries an indication that reads "dental abscess." That is not an oversight to be argued around; it is the reason the guideline exists, and the reason these choices are the treating dentist's to make.

Who it applies to#

Immunocompetent adults with a pulpal or periapical infection in whom a dentist has already decided an antibiotic is indicated. It reaches the dentist writing the prescription and the team member making the three-day call.

It does not apply to children or immunocompromised adults, whose regimens are outside the ADA panel's stated population and outside this page. It does not apply to prophylaxis before a procedure. And it does not replace the decision itself: the sibling entry on the ADA's 2019 guideline is the one that answers when not to prescribe, which is most of the time.

What changed#

The ADA's 2019 guideline was the first evidence-based clinical practice guideline on this question from the ADA, produced by an expert panel convened by the Council on Scientific Affairs and the Center for Evidence-Based Dentistry using the GRADE approach, and it is still the current document. The FDA labels change on their own schedule; the versions read for this entry carry a January 2024 revision date for penicillin V potassium and a July 2026 major change to the dosage section of the cephalexin label. Two of the guideline's framing points are worth noting as changes in practice rather than in text: the panel says there is currently little to no evidence supporting the common belief that a shortened course of antibiotics contributes to antimicrobial resistance, and it instructs dentists to have patients stop 24 hours after complete resolution rather than finish the bottle.

Where the source is#

The link under the title opens the full text of the ADA's 2019 guideline on PubMed Central, free and open access, where the regimen table and every footnote quoted above were read for this entry; the same article sits behind the JADA site, which did not answer requests here. The six FDA labels listed in the downloads were pulled from DailyMed's public API on the database publication date of September 11, 2026 and read in full: amoxicillin, penicillin V potassium, clindamycin hydrochloride, metronidazole and amoxicillin with clavulanate, plus the cephalexin and azithromycin labels whose adult regimens appear in the figure. Labels for the same drug from different manufacturers can differ in formatting, so the setids in the download links identify the exact versions read. Everything here is reported, not recommended: these are labelled and guideline regimens for immunocompetent adults, and the treating dentist decides.